JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating
JMP Securities Adjusts Price Target on Iovance Biotherapeutics to $23 From $25, Maintains Market Outperform Rating
JMP證券將iovance biotherapeutics的目標價從25美元調低至23美元，維持市場跑贏評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊